Abstract:Abstract Background Endoscopy is used to objectively evaluate disease severity in patients with Crohn’s disease (CD), and endoscopic remission is a target for disease control. Ulcer size is associated with longer-term endoscopic remission, so evaluating ulcers may inform longer-term outcomes. Risankizumab (RZB) is an interleukin 23p19 inhibitor approved for adults with moderately to severely active CD. In phase 3 trials, greater proportions of patients with CD achieved endoscopic outcomes including ulcer-free endoscopy with RZB induction and maintenance therapy vs placebo (PBO).1,2 We further investigated the effect of RZB on endoscopic outcomes by evaluating improvements in Simple Endoscopic Score for CD (SES-CD) components during these phase 3 trials. Methods This post hoc analysis used data from the phase 3 induction studies (ADVANCE [NCT03105128] and MOTIVATE [NCT03104413]) and phase 3 maintenance study (FORTIFY [NCT03105102]). Patients received intravenous (IV) doses of RZB (600 mg or 1200 mg) or PBO for 12 weeks, and clinical responders to IV RZB received RZB maintenance therapy (180 mg or 360 mg subcutaneously [SC]) or PBO (withdrawal) for 52 weeks. This analysis evaluated change in SES-CD subscores (size of ulcers, affected surface, and ulcerated surface) at induction week 12 and maintenance week 52 across ileocolonic segments (rectum, left colon, transverse colon, right colon, and ileum); analyses of improvement were based on a nonresponder imputation for patients with baseline subscores > 0 in the specific ileocolonic segment. Data from the induction studies were pooled for analysis; results for RZB 1200 mg IV induction are not reported. Shift data were from patients with available values. Results During the induction and maintenance studies, a numerically greater proportion of patients treated with RZB compared with PBO experienced improvements in any ileocolonic segment in SES-CD size of ulcers, ulcerated surface, and affected surface subscores (Figure). In general across each segment, a numerically greater proportion of patients treated with RZB induction and maintenance therapy compared with PBO experienced improvement from baseline SES-CD size of ulcer subscores of 2 or 3 (diameter 0.5–2 cm or diameter > 2 cm, respectively) to subscores of 0 or 1 (none or diameter 0.1–0.5 cm, respectively) at weeks 12 and 52 (Table). Similar patterns were observed for SES-CD ulcerated surface and affected surface subscores. Safety data for the phase 3 studies have been reported previously. Conclusion Patients treated with RZB experienced greater improvements in SES-CD components compared with PBO during the induction and maintenance studies. References 1. D’Haens G, et al. Lancet. 2022;399:2015–30. 2. Ferrante M, et al. Lancet. 2022;399:2031–46.

S3892 Risankizumab Effectiveness in Perianal Crohn's Disease: A Single Tertiary Care Center Case Series

OP25 Patients with Moderate to Severe Crohn’s Disease with and Without Prior Biologic Failure Demonstrate Improved Endoscopic Outcomes with Risankizumab: Results from Phase 3 Induction and Maintenance Trials

Efficacy and Safety of Risankizumab for Crohn's Disease in Patients from Asian Countries: a Post Hoc Subanalysis of the Global Phase 3 ADVANCE, MOTIVATE, and FORTIFY Studies.

Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 Trial.

Risankizumab Versus Ustekinumab for Moderate-to-Severe Crohn’s Disease

S1198 Endoscopic Response to Risankizumab in Patients With Refractory Crohn's Disease Who Failed Ustekinumab - Real-World Experience

Efficacy and Safety of Risankizumab in the Treatment of Crohn's Disease of the Pouch

S1472 Efficacy of Risankizumab Maintenance Therapy by Clinical Remission and Endoscopic Improvement Status in Patients With Moderately to Severely Active Ulcerative Colitis: Post Hoc Analysis of the COMMAND Phase 3 Study

An evaluation of risankizumab for the treatment of moderate-to-severe ulcerative colitis

P741 Characterisation of endoscopic improvements with risankizumab treatment in patients with moderately to severely active Crohn’s disease

OP06 Risankizumab Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomised Phase 3 COMMAND Study

P848 Risankizumab Effectiveness in Ustekinumab-naïve and Ustekinumab-experienced Patients with Crohn’s Disease- Real-world Data from a Large Tertiary Center

Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid‐free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's disease

Real-world Effectiveness and Safety of Risankizumab in Patients with Moderate to Severe Multirefractory Crohn’s Disease: A Belgian Multicentric Cohort Study

P593 Efficacy of Risankizumab in Patients With Moderately to Severely Active Ulcerative Colitis by Prior Advanced Therapy Failure and Mechanism of Action: Post Hoc Analysis of the INSPIRE and COMMAND Phase 3 Studies

S1156 A Multi-Center Study of the Outcomes of Risankizumab Use Stratified by Prior Ustekinumab Exposure in Patients With Crohn's Disease: A Real-World Experience

Shorter Crohn's Disease Duration Is Associated With Better Clinical and Endoscopic Outcomes With Risankizumab in Phase 3 Studies

DOP76 Individual and comprehensive symptom resolution after induction and maintenance therapy with risankizumab in patients with moderately to severely active Ulcerative Colitis: A post-hoc analysis of INSPIRE and COMMAND studies

Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn’s Disease: Results from the Phase 2 Open-Label Extension Study

P1018 Population pharmacokinetic and exposure-response analyses for efficacy and safety of risankizumab in subjects with moderately to severely active Ulcerative Colitis

DOP18 Efficacy of risankizumab versus ustekinumab by baseline Crohn’s Disease location: post-hoc analysis of the SEQUENCE head-to-head trial